Pfizer requests EUA for oral COVID-19 antiviral treatment
Pfizer today announced its formal request that the Food and Drug Administration authorize the emergency use of its PAXLOVID (PF-07321332; ritonavir) oral antiviral for combating SARS-CoV-2. Pfizer says data from its phase 2/3 clinical trial shows that the drug, which works as a 3CL protease inhibitor, reduced the risk of COVID-19-related hospitalization or death by 89%.
Related News Articles
Headline
For the 2025-2026 school year, exemptions from one or more vaccines among U.S. kindergartners was at 4.2%, increasing from 3.6% for the previous school year,…
Headline
A study published Aug. 5 by Nature found that COVID-19 infection can reactivate dormant, chronic viruses such as Epstein-Barr and cytomegalovirus. The study…
Headline
The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices…
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…
Headline
Flu and COVID-19 vaccination rates among all health care workers for the 2024-25 respiratory virus season was 76.3% and 40.2%, respectively, according to a…
Headline
A study published March 18 by Science Advances estimated that more than 155,000 U.S. COVID-19 deaths were uncounted during the COVID-19 pandemic. Researchers…